| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
As a deuterated internal standard, 3-Methyl-L-histidine-d3 hydrochloride does not have a pharmacological target. The unlabeled compound, 3-Methyl-L-histidine, is an endogenous amino acid derivative found in actin and myosin proteins and serves as a biomarker of muscle protein turnover rather than a drug target.
|
|---|---|
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine is the first deuterated drug to receive Food and Drug Administration approval. This deuterated form of the drug tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease as well as tardive dyskinesia. Ongoing clinical trials suggest that a number of other deuterated compounds are being evaluated for the treatment of human diseases and not merely as research tools.
As an isotope-labeled internal standard, 3-Methyl-L-histidine-d3 hydrochloride itself does not exhibit biological activity. The unlabeled 3-methyl-histidine is a naturally occurring amino acid derivative that is formed by post-translational methylation of histidine residues in actin and myosin, and is used as a marker of muscle protein degradation. |
| ln Vivo |
Deuterated compounds may, in some cases, offer advantages over nondeuterated forms, often through alterations in clearance. Deuteration may also redirect metabolic pathways in directions that reduce toxicities. The approval of additional deuterated compounds may soon follow. Clinicians will need to be familiar with the dosing, efficacy, potential side effects, and unique metabolic profiles of these new entities.
As an isotope-labeled internal standard, 3-Methyl-L-histidine-d3 hydrochloride does not exhibit in vivo activity. The unlabeled 3-methyl-histidine is endogenously produced and released during muscle protein breakdown, and its urinary excretion is used as a non-invasive biomarker for assessing muscle catabolism in various physiological and pathological conditions. |
| Enzyme Assay |
Non-cell-based assay protocols for 3-Methyl-L-histidine-d3 hydrochloride involve LC-MS/MS analysis for quantification of 3-methyl-histidine in biological samples. A typical workflow includes: protein precipitation or solid-phase extraction of plasma, urine, or tissue samples, derivatization if necessary, chromatographic separation on a reversed-phase or HILIC column, and MS/MS detection in MRM mode using the characteristic mass transitions of the deuterated compound.
|
| Cell Assay |
Cell-based assays are not applicable to 3-Methyl-L-histidine-d3 hydrochloride as it is an analytical standard. The unlabeled compound 3-methyl-histidine may be measured in cell culture media or cell lysates as a marker of protein turnover using standard analytical chemistry techniques such as LC-MS/MS or amino acid analysis.
|
| Animal Protocol |
In vivo animal studies with 3-Methyl-L-histidine-d3 hydrochloride are not conducted as it is an analytical standard. The unlabeled compound 3-methyl-histidine is measured in urine or plasma samples from animal models to assess muscle protein breakdown in conditions such as cachexia, aging, or nutritional interventions.
|
| ADME/Pharmacokinetics |
As an isotope-labeled internal standard, 3-Methyl-L-histidine-d3 hydrochloride has no pharmacokinetic properties of its own. The unlabeled 3-methyl-histidine is an endogenous metabolite that is excreted in urine and its levels reflect the rate of muscle protein degradation rather than drug pharmacokinetics.
|
| Toxicity/Toxicokinetics |
As a research-use isotope-labeled compound, 3-Methyl-L-histidine-d3 hydrochloride is not intended for human therapeutic use. Toxicological data are not applicable to this analytical standard. The compound is typically stored at 4°C in a sealed container, protected from moisture and light.
|
| References | |
| Additional Infomation |
3-Methyl-L-histidine-d3 hydrochloride is a stable isotope-labeled internal standard for the quantification of 3-methyl-histidine in biological samples. 3-Methyl-histidine is an established biomarker for muscle protein breakdown and is used in studies of muscle wasting, sarcopenia, and nutritional status assessment. The deuterated form provides accurate quantification by mass spectrometry. It is available as a research reagent for analytical chemistry applications.
|
| Molecular Formula |
C7H9D3CLN3O2
|
|---|---|
| Molecular Weight |
208.66
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~479.25 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7925 mL | 23.9624 mL | 47.9249 mL | |
| 5 mM | 0.9585 mL | 4.7925 mL | 9.5850 mL | |
| 10 mM | 0.4792 mL | 2.3962 mL | 4.7925 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
